These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2420896)

  • 1. Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen.
    Kanayama Y; Kurata Y; McMillan R; Tamerius JD; Negoro N; Curd JG
    J Immunol Methods; 1986 Apr; 88(1):33-6. PubMed ID: 2420896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
    Tamerius JD; Pangburn MK; Müller-Eberhard HJ
    J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.
    Negoro N; Okamura M; Takeda T; Koda S; Amatsu K; Inoue T; Curd JG; Kanayama Y
    Arthritis Rheum; 1989 Oct; 32(10):1233-42. PubMed ID: 2803326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
    Garred P; Mollnes TE; Lea T; Fischer E
    Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay.
    Mollnes TE; Lachmann PJ
    J Immunol Methods; 1987 Aug; 101(2):201-7. PubMed ID: 2440954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.
    Morrow WJ; Williams DJ; Ferec C; Casburn-Budd R; Isenberg DA; Paice E; Snaith ML; Youinou P; Le Goff P
    Ann Rheum Dis; 1983 Dec; 42(6):668-71. PubMed ID: 6606402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification by ELISA of erythrocyte-bound C3 fragments expressing C3d and/or C3c epitopes in patients with factor I deficiency and with autoimmune diseases.
    Møller Rasmussen J; Jepsen HH; Teisner B; Holmskov-Nielsen U; Rasmussen GG; Svehag SE
    Vox Sang; 1989; 56(4):262-9. PubMed ID: 2474900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation in IgA nephropathy.
    Wyatt RJ; Kanayama Y; Julian BA; Negoro N; Sugimoto S; Hudson EC; Curd JG
    Kidney Int; 1987 Apr; 31(4):1019-23. PubMed ID: 3586493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive expression of neoantigenic C3(D) epitopes on bound C3 following activation and binding to different target surfaces in normal and pathological human sera.
    Nilsson B; Ekdahl KN; Svensson KE; Bjelle A; Nilsson UR
    Mol Immunol; 1989 Apr; 26(4):383-90. PubMed ID: 2469949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans.
    Halkjær L; Troldborg A; Pedersen H; Jensen L; Hansen AG; Hansen TK; Bjerre M; Østergaard JA; Thiel S
    Front Immunol; 2020; 11():774. PubMed ID: 32431705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
    Lambris JD; Ganu VS; Hirani S; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4235-9. PubMed ID: 2408276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
    Lachmann PJ; Pangburn MK; Oldroyd RG
    J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A solid-phase anti-C3 assay for detection of immune complexes in six distinguished forms.
    Iida K; Mitomo K; Fujita T; Tamura N
    J Immunol Methods; 1987 Apr; 98(1):23-8. PubMed ID: 2435809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation and antigenic characterization of bound C3 of circulating immune complexes in systemic lupus erythematosus, rheumatoid arthritis, and primary biliary cirrhosis.
    Nilsson B; Bjelle A; Lööf L; Nilsson UR
    J Clin Immunol; 1987 Sep; 7(5):420-6. PubMed ID: 2443529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
    Baatrup G; Svehag SE; Jensenius JC
    Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.